CD19/BCMA dual-target CAR-T therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19/BCMA dual-target CAR-T therapy, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases [NA]